Mesh inlay, mesh kit or native tissue repair for women having repeat anterior or posterior prolapse surgery: randomised controlled trial (PROSPECT)
Autor: | Isobel Montgomery, Alison McDonald, Suzanne Hagen, Mary Kilonzo, Graeme MacLennan, Arb Smith, Kevin Cooper, Suzanne Breeman, Andrew Elders, Dwayne Boyers, Gladys McPherson, C. M. A. Glazener, Christine Hemming, Robert Freeman, John Norrie, Fiona Reid |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
education.field_of_study 030219 obstetrics & reproductive medicine Inlay business.industry Prolapse surgery Population Obstetrics and Gynecology Confidence interval law.invention Surgery 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Sample size determination Relative risk Prolapse Medicine business education Adverse effect |
Zdroj: | 2020, ' Mesh inlay, mesh kit or native tissue repair for women having repeat anterior or posterior prolapse surgery : randomised controlled trial (PROSPECT) ', BJOG: An International Journal of Obstetrics and Gynaecology . https://doi.org/10.1111/1471-0528.16197 Glazener, C, Freeman, R, Breeman, S & Reid, F 2020, ' Mesh inlay, mesh kit or native tissue repair for women having repeat anterior or posterior prolapse surgery: randomised controlled trial (PROSPECT) ', BJOG: an international journal of obstetrics and gynaecology . https://doi.org/10.1111/1471-0528.16197 |
ISSN: | 1471-0528 1470-0328 |
Popis: | Objective To compare standard (native tissue) repair with synthetic mesh inlays or mesh kits. Design Randomised controlled trial. Setting Thirty-three UK hospitals. Population Women having surgery for recurrent prolapse. Methods Women recruited using remote randomisation. Main outcome measures Prolapse symptoms, condition-specific quality-of-life and serious adverse effects. Results A Mean Pelvic Organ Prolapse Symptom Score at 1 year was similar for each comparison (standard 6.6 versus mesh inlay 6.1, mean difference [MD] -0.41, 95% CI -2.92 to 2.11: standard 6.6 versus mesh kit 5.9, MD -1.21 , 95% CI -4.13 to 1.72) but the confidence intervals did not exclude a minimally important clinical difference. There was no evidence of difference in any other outcome measure at 1 or 2 years. Serious adverse events, excluding mesh exposure, were similar at 1 year (standard 7/55 [13%] versus mesh inlay 5/52 [10%], risk ratio [RR] 1.05 [0.66-1.68]: standard 3/25 [12%] versus mesh kit 3/46 [7%], RR 0.49 [0.11-2.16]). Cumulative mesh exposure rates over 2 years were 7/52 (13%) in the mesh inlay arm, of whom four women required surgical revision; and 4/46 in the mesh kit arm (9%), of whom two required surgical revision. Conclusions We did not find evidence of a difference in terms of prolapse symptoms from the use of mesh inlays or mesh kits in women undergoing repeat prolapse surgery. Although the sample size was too small to be conclusive, the results provide a substantive contribution to future meta-analysis. Tweetable abstract There is not enough evidence to support use of synthetic mesh inlay or mesh kits for repeat prolapse surgery. |
Databáze: | OpenAIRE |
Externí odkaz: |